

1 STATE OF OKLAHOMA

2 2nd Session of the 58th Legislature (2022)

3 SENATE BILL 1467

By: David

4
5
6 AS INTRODUCED

7 An Act relating to the state Medicaid program;
8 requiring Oklahoma Health Care Authority to conduct
9 certain annual review; stating purpose; requiring
10 review to include certain criteria; directing
11 Authority to seek public input; requiring utilization
12 of Oklahoma State Health Information Network and
13 Exchange to extent practicable; directing submission
14 and publication of annual report; providing for
15 codification; and providing an effective date.

16 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:

17 SECTION 1. NEW LAW A new section of law to be codified
18 in the Oklahoma Statutes as Section 5026.1 of Title 63, unless there
19 is created a duplication in numbering, reads as follows:

20 A. The Oklahoma Health Care Authority shall conduct an annual
21 review of all medications and forms of treatment for sickle cell
22 disease and services for enrollees with a diagnosis of sickle cell
23 disease. The purpose of the annual review is to determine if the
24 available covered medications, treatments, and services are adequate
25 to meet the needs of enrollees with a diagnosis of sickle cell

1 disease, and whether the Authority should seek to add or recommend
2 additional medications, treatments, or services.

3 B. The review shall include, but not be limited to:

4 1. The extent to which healthcare transitional programs covered
5 under the state Medicaid program prepare, transfer, and integrate
6 emerging adults into the adult care setting from a pediatric
7 setting;

8 2. The extent to which emergency department providers are
9 adequately trained and otherwise prepared to treat and manage sickle
10 cell patients presenting with vaso-occlusive crises including but
11 not limited to the extent to which providers follow clinically
12 validated algorithms and protocols regarding such treatment and
13 management;

14 3. The extent to which sickle cell patients covered under the
15 state Medicaid program are entitled to receive the same standard of
16 care when referred or transferred to an out-of-state facility, and
17 the extent to which the state reimburses such patients for
18 reasonable interstate travel costs; and

19 4. Any additional areas identified by the Authority that impact
20 the care and treatment of individuals in this state living with
21 sickle cell disease or sickle cell trait.

22 C. When conducting the annual review required by this section,
23 the Authority shall solicit and consider input from the general
24 public, with specific emphasis on seeking input from persons or

1 groups with knowledge and experience in the area of sickle cell
2 disease treatment.

3 D. To the extent practicable, the Authority shall utilize the
4 Oklahoma State Health Information Network and Exchange created under
5 Section 1-133 of Title 63 of the Oklahoma Statutes to collect
6 information for the purpose of implementing this section.

7 E. On or before January 15, 2023, and on or before January 15
8 each year thereafter, the Authority shall submit a report to the
9 President Pro Tempore of the Senate and the Speaker of the House of
10 Representatives for distribution to the appropriate subject matter
11 committees that details the Authority's findings from the annual
12 review required by this section and any recommendations to the
13 Legislature based upon those findings. The Authority shall publish
14 the annual report required by this subsection to its website in a
15 manner accessible by the general public.

16 SECTION 2. This act shall become effective November 1, 2022.

17
18 58-2-2571 DC 1/19/2022 8:13:42 PM
19
20
21
22
23
24
25